drugset / Trial / NCT06291415
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, multicenter study to evaluate the safety, tolerability, and efficacy of HMPL-523 in adult subjects with ITP.
Timeline
- Start
- 2024-04-02
- Primary completion
- 2026-04
- Completion
- 2026-11
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sovleplenib | Small molecule | 300 mg | — |
| Subject | Sovleplenib | Small molecule | 400 mg | — |
| Subject | Sovleplenib | Small molecule | 500 mg | — |